Testing of EGFR mutation should be incorporated into the early diagnostic algorithm of NSCLC patients for optimizing treatment strategies and improving patient outcomes, particularly with the advent of EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.